Coya 302 Gets Fast-Track Designation for ALS Treatment

Why It Matters

The fast‑track designation speeds regulatory review and signals that Coya 302 may fill a critical gap in ALS treatment, where no disease‑modifying options exist. Successful outcomes could reshape the therapeutic landscape for neurodegenerative disorders and generate significant commercial value.

Key Takeaways

• FDA grants fast‑track status to Coya 302 for ALS treatment
• Coya 302 pairs low‑dose IL‑2 with CTLA‑4 Ig to rebalance immunity
• Phase 2 ALSTARS trial enrolls 120 newly diagnosed ALS patients
• Early data show some patients stable for up to one year
• Results expected Q1 2027 could reshape ALS therapeutic landscape

Pulse Analysis

Amyotrophic lateral sclerosis remains one of the most lethal neurodegenerative disorders, with median survival of two to five years after diagnosis and no disease‑modifying drugs approved in the United States. In May 2026 the FDA awarded fast‑track designation to Coya 302, a subcutaneous combination of low‑dose interleukin‑2 and the CTLA‑4 immunoglobulin abatacept. By expanding regulatory T‑cells and dampening pro‑inflammatory monocytes, the therapy targets the immune dysregulation that fuels motor‑neuron loss, offering a mechanistic departure from existing symptomatic care.

The company has launched the ALSTARS phase 2 trial, enrolling roughly 120 patients who have been diagnosed within the past six months at about 25 sites across the United States and Canada. Participants receive Coya 302 once or twice monthly, with a placebo arm for comparison, and will be followed for six months before an optional 24‑week blinded extension. Preliminary open‑label data suggest a subset of patients remained stable for six to twelve months, hinting that early immune modulation could slow functional decline and extend quality‑adjusted life years.

If the trial meets its primary endpoints, Coya 302 could become the first therapy to alter the natural history of ALS, shifting the disease from a rapidly fatal trajectory to a manageable chronic condition. The fast‑track status also accelerates regulatory dialogue, potentially shortening the path to market and attracting partnership interest from larger biopharma players. Moreover, the same IL‑2/CTLA‑4 platform has an IND cleared for frontotemporal dementia, indicating a broader application for neurodegenerative diseases driven by regulatory T‑cell dysfunction.